source
- BridgeBio secures up to $1 billion in preferred equity as United Therapeutics invests $140 million to acquire ThymmuneBridgeBio Pharma announced that Sixth Street Partners and HealthCare Royalty will provide up to $1 billion in preferred equity to support its upcoming product launches. The financing is structured…
- FDA approves Tregzi, first T‑reg cell therapy to lower chronic GVHD risk in blood‑cancer transplantsThe FDA announced approval of Tregzi, a regulatory T‑cell based immunotherapy designed to improve chronic graft‑versus‑host disease‑free survival for adults with blood cancers undergoing allogeneic…